article Open AccessTop 1% cited

Two Hundred Gastrointestinal Stromal Tumors

Annals of Surgery · 2000 · Vol. 231(1) · pp. 51–51

Ronald P. DeMatteo(Memorial Sloan Kettering Cancer Center)Jonathan J. LewisDenis H. Y. LeungSatvinder MudanJames M. WoodruffMurray F. Brennan✉(Memorial Sloan Kettering Cancer Center)

View via DOI Publisher page

Abstract

GISTs are uncommon sarcomas. Tumor size predicts disease-specific survival in patients with primary disease who undergo complete gross resection. Tumor recurrence tends to be intraabdominal. Investigational protocols are indicated to reduce the rate of recurrence after resection and to improve the outcome for patients with GIST.

Gastrointestinal Tumor Research and Treatment Sarcoma Diagnosis and Treatment Gastric Cancer Management and OutcomesMedicineGiSTSarcomaMetastasisStromal tumorPrimary tumorAdjuvant therapySurgerySurvival rateDisease

MeSH terms

Actuarial AnalysisAdolescentAdultAgedAged, 80 and overDigestive SystemFemaleGastrointestinal NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesSarcoma

Citations

2,530

FWCI

43.98

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation